Feedback PLC First CE marked release of TexRAD® technology (9059W)
20 November 2017 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 9059W
Feedback PLC
20 November 2017
This announcement contains inside information as stipulated
under the Market Abuse Regulation (EU) No 596/2014 (MAR).
Feedback plc
("Feedback" or the "Company")
First CE marked release of TexRAD(R) technology
Feedback plc (AIM: FDBK), the specialist medical imaging
technology company, announces the first CE marked release of
TexRAD(R) ; the Company's patented quantitative image texture
analysis technology for diagnostic radiological scans.
TexRAD(R) has the potential to assist clinicians in diagnosis,
prognosis and treatment of patients with cancer and is currently
installed in over 40 of the world's leading research institutions
across Europe, North America, Asia and Australasia. Feedback's
subsidiary company, Cambridge Computed Imaging Ltd, has affixed a
CE mark to "TexRAD(R) Lung"; a "software only" Class 1 medical
device providing additional information for the interpretation of
computerised tomography (CT) and positron emission tomography (PET)
scans of patients with lung cancer. The CE mark confirms that
TexRAD(R) Lung meets the requirements of the Medical Device
Directive (MDD - 93/42EEC) ensuring the technology satisfies the
quality, safety and performance standards for medical devices in
the European Union (EU).
Lung cancer has been the most common cancer in the world for
several decades, estimated at 13% of all cancer diagnoses globally.
It is also the most common cause of death from cancer worldwide,
estimated to be responsible for nearly one in five. In the EU alone
there are approximately 417,000 new cases of lung cancer every
year. Radiologists are under significant pressure due to increasing
patient numbers, more examinations required per patient and the
need for earlier diagnosis. By analysing the texture features in CT
scans, TexRAD(R) 's quantitative imaging capabilities provide
clinicians with additional information to make better decisions in
order to improve patient outcomes.
Dr Alastair Riddell, Chairman at Feedback plc, said: "TexRAD(R)
Lung is our first TexRAD(R) product with a CE mark which represents
a significant accomplishment. This development will expedite
TexRAD(R) 's clinical use in the treatment of lung cancer across
the EU, expand its market presence and support the Company's
ongoing commercial discussions for the technology.
"We expect that the rigorous regulatory review required for the
CE mark will pave the way for TexRAD(R) 's clinical use worldwide
and we are now investigating the clinical application of TexRAD(R)
in liver cancer and chronic obstructive pulmonary disease (COPD).
By arming clinicians with disease-specific tools, we believe this
technology has the potential to transform radiological decision
making."
- Ends -
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company.
It develops software and systems that provide innovative techniques
and improved workflows for practitioners involved in medical
research and treating patients. TexRAD(R) , the Company's patented
quantitative image texture analysis technology, has the potential
to assist clinicians in diagnosis, prognosis and treatment of
patients with cancer and is currently installed in over 40 of the
world's leading research institutions across Europe, North America,
Asia and Australasia. The Cadran platform provides a suite of
medical imaging tools for decision support. The Cadran range
includes the picture archiving communication system (PACS) to
provide decision support for scan analysis, diagnostic workstations
which provide secure remote access to view scans on demand, and
products to securely share and transport patient data. Visit
www.fbk.com.
About CE marking
CE marking (and compliance with the directive) is legally
required before placing a device on the market in the EU. An
appropriate quality management system and the preparation of a
technical file are requirements for CE marking. The CE technical
file is a comprehensive description of the device intended to
demonstrate compliance with the Medical Device Directive and
contains extensive documentation on the use, design, risk
assessment, testing, clinical evaluation and manufacture of the
device.
For further information, please contact:
Feedback plc Tel: 01954 718072
Dr Alastair Riddell, Chairman hello@fbk.com
Lara Mott, Investor Relations
Allenby Capital Limited (Nominated Tel: 020 3328
Adviser and Joint Broker) 5656
David Worlidge / James Thomas
Northland Capital Partners Ltd Tel: 020 3861
(Joint Broker) 6625
Patrick Claridge / David Hignell
/ John Howes
Peterhouse Corporate Finance Ltd Tel: 020 7469
(Joint Broker) 0936
Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGMMMMMLNGNZZ
(END) Dow Jones Newswires
November 20, 2017 02:00 ET (07:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024